Company Description
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.
The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products.
Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions.
Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services.
Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems.
The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies.
Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 18, 1997 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 247 |
| CEO | Shawn O'Connor |
Contact Details
Address: 42505 Tenth Street West Lancaster, California 93534-7059 United States | |
| Phone | 661 723 7723 |
| Website | simulations-plus.com |
Stock Details
| Ticker Symbol | SLP |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001023459 |
| CUSIP Number | 829214105 |
| ISIN Number | US8292141053 |
| Employer ID | 95-4595609 |
| SIC Code | 7373 |
Key Executives
| Name | Position |
|---|---|
| Shawn M. O'Connor | Chief Executive Officer |
| Dr. Walter S. Woltosz M.A.S., M.S. | Co-Founder and Chairman |
| William Frederick | Chief Operating Officer, Chief Financial Officer and Secretary |
| John Anthony DiBella M.S. | President of PBPK and Cheminformatics Solutions |
| Jill Fiedler-Kelly M.S. | President of Clinical Pharmacology and Pharmacometrics Services |
| Jennifer Presnell | Accounting Manager |
| Viera Lukacova Ph.D. | Chief Science Officer |
| Dr. Bud Nelson J.D., Ph.D. | Vice President of Corporate Counsel and Personal Data Protection Officer |
| Tanya Marvin | Marketing Manager |
| Lindsay Luke | Executive Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2024 | 10-K | Annual Report |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 18, 2024 | 144 | Filing |
| Sep 3, 2024 | 144 | Filing |
| Aug 23, 2024 | 8-K | Current Report |
| Aug 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 8, 2024 | 10-Q | Quarterly Report |
| Jul 2, 2024 | 8-K | Current Report |